A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
Status:
Terminated
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, single-center, 3-part, study to assess the safety,
tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects
and multiple doses of CC-92252 in adult subjects with psoriasis.